Apricus Biosciences to Present at the 2017 BIO Investor Forum
October 10 2017 - 7:00AM
YASTEST
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical
company advancing innovative medicines in urology and rheumatology,
today announced that Richard Pascoe, Chief Executive Officer, will
present at the 2017 BIO Investor Forum on Wednesday, October 18,
2017, at 9:00 a.m. Pacific Time. The conference will be held
at The Westin St. Francis Hotel in San Francisco, CA. Mr.
Pascoe will provide an update on the Company's strategy and plans
surrounding Vitaros(TM).
A live audio webcast of the presentation can be
accessed via the Investor Relations' section of the Company's
website at www.apricusbio.com. Please log in approximately
5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the
presentation.
About Apricus Biosciences,
Inc.
Apricus Biosciences, Inc. (APRI) is a
biopharmaceutical company advancing innovative medicines in urology
and rheumatology. Apricus has two product candidates currently in
development. Vitaros is a product candidate in the United States
for the treatment of erectile dysfunction, which is in-licensed
from Warner Chilcott Company, Inc., now a subsidiary of Allergan
plc (Allergan). RayVa is our product candidate in Phase 2
development for the treatment of the circulatory disorder Raynaud's
phenomenon, secondary to scleroderma, for which we own worldwide
rights.
For further information on Apricus, visit
http://www.apricusbio.com.
Vitaros(TM) is Apricus' trademark in the United
States, which is pending registration and subject to the agreement
with Allergan. Vitaros® is a
registered trademark of Ferring International Center S.A. in
certain countries outside of the United States. RayVa(TM) is
Apricus' trademark, which is registered in certain countries
throughout the world and pending registration in the United
States.
CONTACT: Matthew Beck
mbeck@troutgroup.com
The Trout Group
(646) 378-2933
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Apr 2023 to Apr 2024